Intravenous administration of nifekalant hydrochloride for the prevention of ischemia-induced ventricular tachyarrhythmia in patients with renal failure undergoing hemodialysis.
Excretion in the urine is an important pathway for the elimination of nifekalant hydrochloride (NIF), a novel class III antiarrhythmic agent. Three patients with renal failure were undergoing hemodialysis and receiving NIF for the prevention of ischemia-induced ventricular tachyarrhythmia. Because NIF is not dialyzed, dose adjustment at relatively low concentrations was required, with monitoring of the QT interval.
Myoishi
Masafumi
M
Division of Cardiology, National Cardiovascular Center, Osaka, Japan.
Yasuda
Satoshi
S
Miyazaki
Shunichi
S
Ueno
Kazuyuki
K
Morii
Isao
I
Satomi
Kazuhiro
K
Otsuka
Yoritaka
Y
Kawamura
Atsushi
A
Kurita
Takashi
T
Kamakura
Shiro
S
Nonogi
Hiroshi
H
D000368:Aged; D000889:Anti-Arrhythmia Agents / Q000008:administration & dosage* / Q000493:pharmacokinetics; D003928:Diabetic Nephropathies / Q000150:complications / Q000628:therapy; D016903:Drug Monitoring; D004562:Electrocardiography; D006801:Humans; D007275:Injections, Intravenous; D008297:Male; D017202:Myocardial Ischemia / Q000150:complications; D011744:Pyrimidinones / Q000008:administration & dosage* / Q000493:pharmacokinetics; D006435:Renal Dialysis; D051437:Renal Insufficiency / Q000150:complications / Q000628:therapy; D017180:Tachycardia, Ventricular / Q000209:etiology / Q000517:prevention & control*
D000889:Anti-Arrhythmia Agents; D011744:Pyrimidinones; C076259:nifekalant